scholarly journals DBDP SAR Microstrip Array Technology

10.5772/15597 ◽  
2011 ◽  
Author(s):  
Shun-Shi Zhong
Keyword(s):  
Array Technology ◽  
Microstrip Array

scholarly journals Microstrip array technology

1981 ◽  
Vol 29 (1) ◽  
pp. 25-37 ◽  
Author(s):  
R. Mailloux ◽  
J. McIlvenna ◽  
N. Kernweis
Keyword(s):  
Array Technology ◽  
Microstrip Array

Fast Computation of Electrical Property of Microstrip Array with AIM

2011 ◽  
Vol 30 (1) ◽  
pp. 238-240
Author(s):  
Xiu-lian He ◽  
Wen-jun Gao ◽  
Yi-cai Ji ◽  
Hong Lei ◽  
Shu-xi Gong
Keyword(s):  
Electrical Property ◽  
Fast Computation ◽  
Microstrip Array

scholarly journals Introduction

1995 ◽  
Vol 167 ◽  
pp. 3-7
Author(s):  
A. G. Davis Philip
Keyword(s):  
Large Field ◽  
Direct Imaging ◽  
Ir Detector ◽  
New Developments ◽  
Detector Arrays ◽  
Array Detectors ◽  
Poster Sessions ◽  
Array Technology ◽  
The Subject ◽  
Scientific Results

A short introduction to the subject of the meeting, IAU Symposium No. 167, New Developments in Array Technology and Applications is given. CCD and Array detectors have become the detectors of choice at optical observatories all over the world. Direct imaging, photometry and spectroscopy are all vastly improved as a result. Thirteen IAU Commissions joined in sponsoring this meeting which indicates the wide interest in this subject. In the five days of the symposium the following topics were discussed: New Developments in CCD Technology, New Developments in IR Detector Arrays, Direct Imaging with CCDs and Other Arrays, Spectroscopy with CCDs and Other Arrays and Large Field Imaging with Array Mosaics. A few papers concerning Astrometry with CCDs were given in the poster sessions. Scientific results were also presented in the poster sessions.

A Metabolite Array Technology for Precision Medicine

2021 ◽  
Vol 93 (14) ◽  
pp. 5709-5717
Author(s):  
Guoxiang Xie ◽  
Lu Wang ◽  
Tianlu Chen ◽  
Kejun Zhou ◽  
Zechuan Zhang ◽  
...  
Keyword(s):  
Precision Medicine ◽  
Array Technology

scholarly journals Identification of potential autoantigens in anti-CCP-positive and anti-CCP-negative rheumatoid arthritis using citrulline-specific protein arrays

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Thomas B. G. Poulsen ◽  
Dres Damgaard ◽  
Malene M. Jørgensen ◽  
Ladislav Senolt ◽  
Jonathan M. Blackburn ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Protein Microarray ◽  
Specific Protein ◽  
Immune Reactivity ◽  
Igg Antibodies ◽  
Native Proteins ◽  
Array Technology ◽  
Citrullinated Proteins ◽  
Folded Proteins

AbstractThe presence or absence of autoantibodies against citrullinated proteins (ACPAs) distinguishes two main groups of rheumatoid arthritis (RA) patients with different etiologies, prognoses, disease severities, and, presumably, disease pathogenesis. The heterogeneous responses of RA patients to various biologics, even among ACPA-positive patients, emphasize the need for further stratification of the patients. We used high-density protein array technology for fingerprinting of ACPA reactivity. Identification of the proteome recognized by ACPAs may be a step to stratify RA patients according to immune reactivity. Pooled plasma samples from 10 anti-CCP-negative and 15 anti-CCP-positive RA patients were assessed for ACPA content using a modified protein microarray containing 1631 different natively folded proteins citrullinated in situ by protein arginine deiminases (PADs) 2 and PAD4. IgG antibodies from anti-CCP-positive RA plasma showed high-intensity binding to 87 proteins citrullinated by PAD2 and 99 proteins citrullinated by PAD4 without binding significantly to the corresponding native proteins. Curiously, the binding of IgG antibodies in anti-CCP-negative plasma was also enhanced by PAD2- and PAD4-mediated citrullination of 29 and 26 proteins, respectively. For only four proteins, significantly more ACPA binding occurred after citrullination with PAD2 compared to citrullination with PAD4, while the opposite was true for one protein. We demonstrate that PAD2 and PAD4 are equally efficient in generating citrullinated autoantigens recognized by ACPAs. Patterns of proteins recognized by ACPAs may serve as a future diagnostic tool for further subtyping of RA patients.

scholarly journals Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
S. Dhara ◽  
S. Chhangawala ◽  
H. Chintalapudi ◽  
G. Askan ◽  
V. Aveson ◽  
...  
Keyword(s):  
Low Cost ◽  
Disease Free Survival ◽  
Chromatin Accessibility ◽  
Cancer Prognosis ◽  
Ductal Adenocarcinoma ◽  
Binding Motifs ◽  
Free Survival ◽  
Array Technology ◽  
Treatment Naïve ◽  
Generation Sequencing

AbstractUnlike other malignancies, therapeutic options in pancreatic ductal adenocarcinoma (PDAC) are largely limited to cytotoxic chemotherapy without the benefit of molecular markers predicting response. Here we report tumor-cell-intrinsic chromatin accessibility patterns of treatment-naïve surgically resected PDAC tumors that were subsequently treated with (Gem)/Abraxane adjuvant chemotherapy. By ATAC-seq analyses of EpCAM+ PDAC malignant epithelial cells sorted from 54 freshly resected human tumors, we show here the discovery of a signature of 1092 chromatin loci displaying differential accessibility between patients with disease free survival (DFS) < 1 year and patients with DFS > 1 year. Analyzing transcription factor (TF) binding motifs within these loci, we identify two TFs (ZKSCAN1 and HNF1b) displaying differential nuclear localization between patients with short vs. long DFS. We further develop a chromatin accessibility microarray methodology termed “ATAC-array”, an easy-to-use platform obviating the time and cost of next generation sequencing. Applying this methodology to the original ATAC-seq libraries as well as independent libraries generated from patient-derived organoids, we validate ATAC-array technology in both the original ATAC-seq cohort as well as in an independent validation cohort. We conclude that PDAC prognosis can be predicted by ATAC-array, which represents a low-cost, clinically feasible technology for assessing chromatin accessibility profiles.

Sign in / Sign up

Export Citation Format

Share Document